-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Myelofibrosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Myelofibrosis Drug Details: Orca-Q is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Myelodysplastic Syndrome Drug Details: Orca-Q is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Orca-Q is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drug Details: Orca-Q is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Orca-Q in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drug Details: Orca-Q is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zatolmilast in Fragile X Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Zatolmilast in Fragile X SyndromeDrug Details:BPN-14770 is under development for the treatment of fragile X syndrome,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FOL-100 in Androgenic Alopecia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.FOL-100 in Androgenic AlopeciaDrug Details:FOL-100 is under development for the treatment of male androgenetic alopecia. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986218 in Colorectal Cancer Drug Details: BMS-986218 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Camidanlumab Tesirine in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Camidanlumab tesirine in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details: Camidanlumab tesirine is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Camidanlumab Tesirine in Myelodysplastic Syndrome
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Camidanlumab tesirine in Myelodysplastic Syndrome Drug Details: Camidanlumab tesirine is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.